A Controlled Trial of Losartan in Posttraumatic Stress Disorder
Status:
Completed
Trial end date:
2020-09-29
Target enrollment:
Participant gender:
Summary
This study is being conducted to determine if losartan, an angiotensin receptor blocker
(ARB), is safe and effective in the treatment of posttraumatic stress disorder (PTSD)
symptoms. The study is also intended to determine if certain genetic markers are useful in
predicting PTSD symptom reduction with losartan. Approximately 160 subjects with chronic PTSD
ages 18-65 will participate in this study across five sites. Subjects will be assigned by
chance to take either flexibly dosed losartan (up to a maximum dosage of 100 mg) or placebo
(which resembles the study drug but has no active ingredients), once a day for 10 weeks.
Furthermore, it is hypothesized that CC homozygotes for rs4311 SNP in the ACE gene will have
a superior response to losartan on PTSD symptoms compared to T carriers.
Phase:
N/A
Details
Lead Sponsor:
University of California, San Diego
Collaborators:
Atlanta Research and Education Foundation Foundation for Atlanta Veterans Education and Research, Inc. George Washington University Henry M. Jackson Foundation, Walter Reed National Military Medical Center Massachusetts General Hospital Mclean Hospital NYU Langone Health